Auxilium Pharmaceuticals — Investor Day (October 2007)
188 slides from Auxilium Pharmaceuticals's investor day presentation, Oct 17, 2007
Slide 1: Welcome to Auxilium's First Analyst Day – Focusing on Xiaflex
Welcome to Auxilium’s First Analyst Day – Focusing on Xiaflex! October 17, 2007 Exhibit 99.1
Slide 2: Armando Anido, Chief Executive Officer and President
Armando Anido Chief Executive Officer and President
Slide 3: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding future Testim market share and sales growth a
Slide 4: Today's Agenda
Today’s Agenda Who is AUXL Overview of XIAFLEX™ Dupuytren’s Contracture ~ Disease overview & treatment options ~ Clinical Development Plan ~ Market Overview Peyronie’s Disease ~ Disease overview & treatment options ~ Clinical Development Plan ~ Market Overview Questions and Answers
Slide 5: Ground Rules For The Day
Ground Rules For The Day • Please hold all questions until after we finish the formal presentations. • We will limit each person to 1 question, then allow you to get back in the queue • We may limit responses from our guest speakers to preserve competitive data or intellectual property rights •Speak
Slide 6: Medical Experts Participating Today
Medical Experts Participating Today • Larry Hurst, M.D., Professor and Chair, Chief of Hand Surgery, Department of Orthopaedics of the Health Science Center, State University of New York at Stony Brook • Gerald H. Jordan, M.D., F.A.C.S., F.A.A.P., Professor, Department of Urology, Eastern Virginia M
Slide 7: Participating from Auxilium
Participating from Auxilium Jim Fickenscher, Chief Financial Officer Roger Graham, Executive Vice President, Sales & Marketing Dr. Jyrki Mattila, Executive Vice President, Business Development, R&D and Technical Operations
Slide 8: Fastest Growing TRT Product, Late Stage Company
Fastest Growing TRT product in the U.S. Late Stage Company Transforming Product Poised for Growth + =
Slide 9: Auxilium Pharmaceuticals, Inc.
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa . ~ Manufacturing in Horsham, Pa. ~ Approximately 2
Slide 10: Broad Pipeline Maturing in Coming Years
Market Phase III Phase II Phase I Hypogonadism Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Overactive Bladder Broad Pipeline Maturing in Coming Years Broad Pipeline Maturing in Coming Years Note: Worldwide rights for all products available, except Testim where ex -U.S. rights
Slide 11: XIAFLEX – Company Transforming Opportunity
XIAFLEX – XIAFLEX – Company Transforming Company Transforming Opportunity Opportunity • Potential to replace surgery • Great fit for Specialty Biopharmaceutical Company • Worldwide rights offer options to build company or generate cash • We believe there are approximately 450,000 potential patients
Slide 12: Overview of XIAFLEX
Overview of XIAFLEX™ (Clostridial Collagenase for Injection)
Slide 13: XIAFLEX
XIAFLEX™ • Purified Clostridial Collagenase for injection • Specific combination of several subtypes of Collagenase • Produced by bacterial fermentation & purified at our Horsham facility • Filled and lyophilized by a third party manufacturing partner • Requires reconstitution with sterile diluent b
Slide 14: Mechanism of Action
Mechanism of Action • Collagen is a molecule made up of three peptide chains arranged as an alpha-triple helix ~ Renders collagen impervious to all proteolytic enzymes except collagenase Endogenous collagenases ~ May be deficient in Dupuytren’s & Peyronie’s patients ~ Degrade collagen at one site &
Slide 15: XIAFLEX
XIAFLEX™ • Over 1,300 patients have been exposed to XIAFLEX™ in a range of indications • 237 Dupuytren’s patients have been treated • 280 Peyronie’s patients have been treated
Slide 16: Development History
Development History • First formulated in the 1980’s • Initial trials in Peyronie’s Disease – 1982 • Initial trials in Dupuytren’s Contracture – 1996 • Orphan Drug Designations Granted ~ Dupuytren’s Contracture – 1996 ~ Peyronie’s Disease – 1997 Auxilium Obtains License to AA4500 - 2004 • Initial Du
Slide 17: Development History
Development History • New manufacturing process developed – 2004 to 2006 • Option exercised for Frozen Shoulder – December, 2005 • Horsham manufacturing facility acquired – August, 2006 • Results announced from ~ Initial Phase 3 study in Dupuytren’s contracture – June, 2006 ~ Phase 2 studies in Peyr
Slide 18: Lawrence C. Hurst, MD
Lawrence C. Hurst, MD Current Professional Appointments: ~ Professor & Chairman; Chief, Division of Hand Surgery, Department of Orthopaedics, SUNY @ Stony Brook School Of Medicine ~ Program Director, Hand Fellowship Training ~ Adjunct Staff/Hand Surgery: St. Charles Hospital, Port Jefferson, NY Educ
Slide 19: Dupuytren's Disease
Dupuytren’s Disease. IK
Slide 20: History of Dupuytren's Disease
History of Dupuytren’s Disease (DD) • Orkney and Iceland in th & th writings mention DD • Felix Plater of Basel describes DD in 1614 but thought pathology secondary to tendon problem • John Hunter accurately describes DD in 1777 – the year of Dupuytren’s birth • Ashley Copper writes about DD in “A t
Slide 21: History
History The eponym for Dupuytren Disease was coined because M. Dupuytren performed a fasciotomy using an open transverse incision in 1831
Slide 22: History of DD
History of DD Despite Dupuytren’s famous open surgical treatment, Ashley Cooper’s closed fasciotomy was the treatment of choice but neither procedure was used frequently until anesthesia was added in 1842 and Lister’s antiseptic techniques were added in 1865.
Slide 23: Dupuytren's Disease
Dupuytren’s Disease _ Lawrence C..Hurst;MD University Hand Cent
Slide 24: Histology, Cell Biology & Biochemistry
HISTOLOGY, CELL BIOLOGY & BIOCHEMISTRY The Myofibroblast and Attached collagen Electron Microscopic view of a Myofibroblast
Slide 25: Histology, Cell Biology & Biochemistry
HISTOLOGY, CELL BIOLOGY & BIOCHEMISTRY Increased collagen type III & GAG’s Collagen helix pattern with increased cross- links Fibrotactin - an extracellular matrix- cytoskeletal connector
Slide 26: Dupuytren's Disease
Dupuytren’s Disease _ Lawrence C..Hurst;MD University Hand Cent
Slide 27: Dupuytren's Disease – Normal
Dupuytren’s Disease| NORMAL
Slide 28: Dupuytren's Disease – Abnormal
Dupuytren’s Disease| ABNORMAL
Slide 29: Pathoanatomy: Common Pathologic Cords
PATHOANATOMY Common Pathologic Cords Central Cord Lateral Cord Natatory Cord Pretendinous Cord Spiral Cord Nodule
Slide 30: Pathoanatomy
PATHOANATOMY Digital Nerve and Vessel Spiral Cord Note: Cord Actually Straight and the Neurovascular bundle spirals!
Slide 31: Incidence, Genetics, Associated Diseases, Ectopic Locations
Incidence • Genetics Associated Diseases Ectopic Locations
Slide 32: Incidence
INCIDENCE Mikkelsen in Norway found 9% incidence in males & 3% incidence in females Incidence: near 5% before age 20 above 20% at age 70 Brenner (2001) found 1.9 Million Germans affected
Slide 33: Dupuytren's Disease Incidence by Age
Dupuytren’s Disease ™ Incidence (%) Age (yrs.)
Slide 34: Genetics: Autosomal Dominant
GENETICS: Autosomal dominant Mendelian Inheritance pattern with variable penetrance:
Slide 35: Ectopic Fibromatoses
ECTOPIC FIBROMATOSES: - Foot – Plantar fibromatosis (Ledderhose) - Penile Fibromatosis (Peyronie) - Knuckle Pads
Slide 36: Ectopic Fibromatoses
ECTOPIC FIBROMATOSES: - Foot – Plantar fibromatosis (Ledderhose)
Slide 37: Treatment Options – Current Option: Surgery
Treatment Options Current Option - Surgery
Slide 38: Surgical Indications
Surgical Indications • 30 Degree MP Contracture • Any PIP Contracture • Nodule Over Trigger Finger Requiring Surgery • Anesthesia – Match type with Patient & Contracture-Local, Axillary Block or General
Slide 39: Surgical Indications
Surgical Indications • Positive Table Top Test The Dupuytren’s cord causes flexion contractures so that the palm and the fingers CAN NOT be placed on the same flat surface simultaneously !!
Slide 40: Surgical indications suggest operating on mild contractures
• These surgical indications suggest that surgeons recommend operative treatment for rather mild contractures. Why are these the standard textbook indications?
Slide 41: Progressive, severe contractures are difficult to correct
• Progressive - sometimes even aggressive. • Severe contractures are very difficult to correct surgically • Severe contractures can interfere significantly with activities of daily living (ADL)
Slide 42: Severe Contracture Can Cause Hygiene Problem
Severe Contracture Can Cause Hygiene Problem Pre-op photo shows Dupuytren’s cord eroding through the skin pit base at first flexion crease of the finger
Slide 43: Imagine this hand getting into this pocket
Imagine this hand easily getting into this pocket??
Slide 44: Imagine this hand holding this mug of beer
Imagine this hand holding this mug of beer?
Slide 45: Imagine this hand trying to wash your face
Imagine this hand trying to wash your face?
Slide 46: Imagine this hand shaking your hand
Imagine this hand shaking your hand?
Slide 47: Many incisions have been tried over last century
Many incisions have been tried over last century No incision has made surgery simple; always successful or guaranteed a long term correction!
Slide 48: Common Incisions for Operative Management
COMMON USED INCISONS FOR OPERATIVE MANAGEMENT ARE: Brunner(zig-zag plasty), Standard Z-plasty, Or McCash (Transverse)
Slide 49: Operative Management in DD
Operative Management in DD Distally Based Flap
Slide 50: Operative anatomy
|skoog’s ligament us band cular Bun
Slide 51: Operative Management in DD: Spiral Cords
Operative Management in DD Spiral Cords Digital nerve superficial to the spiral cord Spiral cord moves N-V Bundle Proximally, Centrally and Superficially
Slide 52: Dupuytren's Disease
|/Dupuytren’s Disease
Slide 53: Pre-tendonous Cord
Pre-tendonous Cord in: Cord out: Excised Dupuytren’s Cord
Slide 54: With tourniquet down
With tourniquet down check: Flap vascularity:
Slide 55: Surgical Treatment can be very extensive
Surgical Treatment can be very extensive !
Slide 56: Open Palm (McCash) Technique
Operative Management in DD : OPEN Palm ( McCash ) Technique At Surgery 2-3 Months Post-op
Slide 57: Operative Management of DD in the Radial Side of the Hand
Operative Management of DD in the Radial Side of the Hand: Contracting Web Superficial and Deep Commissurial Cords
Slide 58: Skin Grafts
Skin Grafts Cord tissue New Skin graft Healed graft from previous surgery Skin Grafts
Slide 59: Lawrence C. Hurst, MD
Lawrence. C..| H urst;,MD
Slide 60: Prognosis – McFarlane
PROGNOSIS – Mc Farlane 1202 Surgical patients 6-18 months Follow-up: -19% Perfect - 56% Improved - 25% same or worse
Slide 61: Closed fasciotomy can be dangerous
Another Surgical Option is the Closed fasciotomy which CAN BE DANGEROUS! Why? - Because This NERVE Might Be Right Here!
Slide 62: Needle fasciotomy can be dangerous to digital nerves
Another Surgical Option is the Needle fasciotomy. This too can be dangerous to digital nerves.
Slide 63: Operative Management in DD: Needle fasciotomy
Operative Management in DD: Needle fasciotomy
Slide 64: Needle fasciotomy Nerve, follow-up
Operative Management in DD: Needle fasciotomy Nerve, f/u
Slide 65: Non-Operative Management: XIAFLEX
Non-Operative Management: XIAFLEX • Indications = Surgical Indications !
Slide 66: Non-Operative Management: XIAFLEX
Non-Operative Management: XIAFLEX* *Currently not FDA approved .25 CC’s for MP and .20 CC’s for PIP Each with 0.58 mg of Xiaflex which equals 10,000 units
Slide 67: XIAFLEX Target areas for injection
Non-Operative Management: XIAFLEX* Distal End Of Cord Proximal End Of Cord Area of Maximal “Bowstringing” (Separation of Cord and Flexor Tendons) Target areas for Xiaflex Injection *Currently not FDA approved
Slide 68: Non-Operative Management: XIAFLEX
Non-Operative Management: XIAFLEX* *Currently not FDA approved 1/3 of dose in three separate places In the cord (not through the cord)
Slide 69: Non-Operative Management
Non-Operative Management The needle should be placed in, not through the gritty gristly consistency of the cord (can be palpated with the end of the needle)
Slide 70: Non-Operative Management of Y Shaped Cord
Non-Operative Management of “Y” Shaped Cord *Currently not FDA approved 1/3 of dose in three separate places In the cord (not through the cord) • Created by a combination of a central and natatory cord • The “point” of the Y should be injected
Slide 71: XIAFLEX Clinical Study Results
XIAFLEX Clinical Study Results
Slide 72: Summary of Clinical Studies
Summary of Clinical Studies Total § Open label study of the relative safety and efficacy of collagenase therapy in the treatment of residual type Dupuytren’s disease. DUPY- (continuat ion from - 303) (12 of 35 subjects had placebo only) Double-blind randomized, placebo controlled study of the relati
Slide 73: Overview Of Clinical Data
Overview Of Clinical Data • 215 patients with Dupuytren’s contracture treated with Xiaflex – 0.58mg per injection appears to be the most effective dosage – One Phase 3 study with 35 patients completed
Slide 74: Overview (cont.)
Overview (cont.) • Two double-blind, placebo controlled trials – One Phase 2: 80 subjects – One Phase 3: 35 subjects • Clinical Success: return to within –5 of normal O O
Slide 75: Efficacy Profile - DUPY Double Blind Exploratory
Efficacy Profile - DUPY 101 Double Blind Exploratory • One injection • 49 subjects • AA4500 Success (Primary Joint) – MP 14/18 = 78% – PIP 5/7 = 71% JHS 27A, 5, p.788-798 (2002)
Slide 76: Efficacy Profile - DUPY Double Blind Phase
Efficacy Profile - DUPY 202 Double Blind Phase 2 • One injection • 80 subjects • AA4500 Success (Primary Joint) – MP 13/16 = 81% – PIP 5/7 = 71% JHS 27A, 5, p.788-798 (2002)
Slide 77: Efficacy Profile - DUPY Double Blind Phase
Efficacy Profile - DUPY 303 Double Blind Phase 3 XIAFLEX Placebo P-value Primary End Point 21/23 (91%)* < .001 - MP Joint 12/14 (86%) < .001 - PIP Joint 9/9 (100%) < .001 Secondary Joint 5/6 (83%) .035 Median Time to Success 8 Days N/A Mean # Injections For Success 1.4 N/A * Success rates were 70% a
Slide 78: Efficacy Profile – Summary from DB studies
Efficacy Profile – Summary from DB studies • MP joints: 81% (one injection) to 86% (multiple injections) • PIP joints: 71% (one injection) to 100% (multiple injections)
Slide 79: Safety Profile
Safety Profile (202 & 303) • Generally well tolerated • Treatment-related AEs confined to the local / administration site – Related to the injection or manipulation procedure of rupturing the cord • Mild or moderate, non-serious, transient, and resolved within 2 - 4 weeks without sequelae.
Slide 80: Summary
Summary •Excellent efficacy profile, ranging from 71% - 100% after up to three injections •Most achieved clinical success within one month •General well tolerated after multiple injections •AEs confined locally and were mild, moderate, and resolved with 2- 4 weeks •In 202, no indication of antibody
Slide 81: Non-Operative Management: XIAFLEX
Non-Operative Management: XIAFLEX* year old male complaining of inability to straighten his right little finger for the past 3 years. It “gets in my way!” Exam shows an MP contracture. post treatment *Currently not FDA approved
Slide 82: Non-Operative Management: XIAFLEX
Non-Operative Management: XIAFLEX* y.o. male with severe recurrent DD Of the long finer. post treatment *Currently not FDA approved
Slide 83: Non-Operative Management: XIAFLEX
Non-Operative Management: XIAFLEX* y.o. male complaining of a contracture of his left little finger present for five years. He can’t put his hand in his pocket and puts his finger in his eye while washing his face. Exam shows a PIP contracture post treatment *Currently not FDA approved
Slide 84: Dupuytren's Disease
Dupuytren’s Disease}
Slide 85: Dupuytren's Disease
Dupuytren’s Disease q Lawrence. C..Hurst,;MD University Hand ¢ Department Of Or
Slide 86: Clinical Program for Dupuytren's Contracture
Clinical Program for Dupuytren’s Contracture Jyrki Mattila Executive Vice President R&D
Slide 87: Suspended Phase Studies
Suspended Phase 3 Studies • First clinical trials utilizing XIAFLEX ™ manufactured under process developed by Auxilium • Six sites in Australia and United States participated • Thirty patients were treated ~ 22 received XIAFLEX ™ ~ 8 received placebo injections • of patients injected with XIAFLEX ™
Slide 88: XIAFLEX Clinical Phase 3 Program
Xiaflex ™ Clinical Phase 3 Program CORD I Phase 3 double blind study with open label extension in the United States CORD II Phase 3 double blind study with open label extension in Australia JOINT I Open label phase 3 study in the United States JOINT II Open label phase 3 study in Australia and Europ
Slide 89: CORD I
CORD I C ollagenase O ption for R eduction of D upuytren ’ s ------------------------- A Phase 3, Double-Blind, Randomized, Placebo - Controlled Study of Xiaflex ™ in the Treatment of Dupuytren’s Contracture
Slide 90: Objectives – CORD I
Objectives – CORD I Primary efficacy objective • Reducing the degree of contracture of the primary MP or PIP joints Secondary efficacy objective • Reducing the degree of contracture in multiple MP and PIP joints Safety Objective • Provide data on the tolerability of Xiaflex ™ up to months post first
Slide 91: Study Design – CORD I
Study Design – CORD I Total of 216 subjects will be enrolled in approximately 15 study sites in the United States • Subjects stratified by ~ the primary joint type (144 MP joints and 72 PIP joints) ~ severity of primary joint contracture (< > 50 ° /40 ° for MP/PIP joints, respectively) • Subjects ra
Slide 92: Inclusion Criteria – CORD I
Inclusion Criteria - CORD I Dupuytren’s Contracture of at least one finger, • At least 20 ° but no greater than 100 ° for MP joint • At least but no greater than 80 ° for PIP joint • Caused by a palpable cord that has never been treated with Xiaflex ™ . Subject has a positive “table top test”
Slide 93: Treatment and Follow-up – CORD I
Treatment and Follow-up – CORD I Double blind placebo controlled phase (3 month): • Maximum of 3 injections of study drug (Day 0, 30, and 60). • Follow-up visits will be 1, 7 and 30 days after each injection. Open label extension (9 months): Nine month follow-up after completion of the double blind
Slide 94: Efficacy Definitions – CORD I
Efficacy Definitions – CORD I PRIMARY EFFICACY ENDPOINT: • The proportion of subjects who achieve clinical success of the primary joint after up to three injections Clinical success : Reduction in contracture to < 5 ° of normal 30 days after last injection.
Slide 95: Secondary efficacy endpoints – CORD I
Secondary efficacy endpoints – CORD I Recorded for the primary joint • Clinical success after the first injection • Clinical improvement • Percent reduction from baseline in contracture • Percent change from baseline in range of motion • Time to reach clinical success Clinical improvement : A > 50%
Slide 96: Expected Timeline – CORD I
Expected Timeline – CORD I • Enrollment completed by end of 2007 • Top line results of the double blind portion available 2Q 2008 • 12 month follow-up completed by end of 2008 • Study ready for BLA submission early 2009
Slide 97: CORD II
CORD II 60 patients, following protocol similar to CORD I • 3 month double blind • 9 month open label Five study sites in Australia Top line data from the double blind portion expected to be available 2Q 2008
Slide 98: JOINT I & II
JOINT I & II J oint O pen - Label I njection N on - Surgical T reatment ------------------------- Phase 3, Open-Label Studies of the Safety and Efficacy of Xiaflex ™ in the Treatment of Dupuytren’s Contracture
Slide 99: Design – JOINT I & II
Design - JOINT I & II Objective : To evaluate the safety and efficacy of up to 5 injections of Xiaflex ™ in multiple joints of subjects with Dupuytren’s contracture • No placebo control, all subjects receive Xiaflex ™ • JOINT I includes approximately 10 sites in the United States and enrolls 100 sub
Slide 100: Design – JOINT I & II
Design - JOINT I & II • Inclusion and exclusion criteria same as in CORD I • Efficacy definitions same as in CORD I • Following safety endpoints will be monitored: ~ Adverse events ~ Clinical laboratory tests and vital signs ~ Grip strength of the treated hand ~ Immunogenicity
Slide 101: Clinical Phase 3 Program Summary
Clinical Phase 3 Program Summary : • All studies up and running at this point •Enrollment to CORD I and CORD II expected to complete by end of 2007 •Approximately 725 subjects are planned to be enrolled in total •Phase 3 program to complete to allow BLA submission early 2009
Slide 102: Market Overview for XIAFLEX: Dupuytren's Disease
Market Overview for XIAFLEX: Dupuytren ’ s Disease Roger D. Graham, Jr. Executive Vice President Sales & Marketing
Slide 103: Market Research Methodology
Market Research Methodology • Approximately 600 Orthopedic and Hand Surgeons ~ 415 U.S. Physicians ~ 193 E.U. Physicians Qualitative and Quantitative Research ~ on in depth interviews with KOLs (High Treaters) ~ Web based Surveys ~ Second quantitative study designed to provide 95% confidence level a
Slide 104: Surgeon's Motivation To Use XIAFLEX
Surgeon’s Motivation To Use XIAFLEX • Dissatisfied With Surgery ~ Flexion contractures often not fully corrected (especially PIP joints) ~ High rate of complications ~ Difficult to meet patients’ expectations Believe XIAFLEX Fills An Unmet Need ~ Earlier use than surgery ~ Appropriate for poor surgi
Slide 105: Reimbursement and Surgical Costs
Reimbursement and Surgical Costs • Reimbursement ~ All payers anticipate coverage for XIAFLEX, including EU ~ New CPT codes may be needed for injection & manipulation ~ Miscellaneous J-code at launch Surgical Costs - Ambulatory (99%) ~ $ 4,800* • In-patient Surgery ~ $12,000 ** * Pharmetrics ** Veri
Slide 106: XIAFLEX Potential: Dupuytren's Contracture
XIAFLEX Potential: Dupuytren’s Contracture Patients Seeking Treatment ~1.03M No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 XIAFLEX Potential Candidates
Slide 107: Xiaflex Commercial Opportunity
Xiaflex Commercial Opportunity We believe: There is a pent-up demand for non-surgical therapy Surgeons and patients prefer non-invasive treatment Each patient on average has 2.2 joints which will require treatment; 49% have contractures in both hands Early data indicates on average 1.4 vials of XIAF
Slide 108: Gerald H. Jordan, MD, FACS, FAAP
Gerald H. Jordan, MD, FACS, FAAP Current Professional Appointments: ~ Professor Urology Department, Eastern Virginia Medical School ~ Director, The Devine Center For Genitourinary Reconstruction, Sentara Norfolk General Hospital Education: ~ MD Degree: University of Texas Health Sciences Center Medi
Slide 109: Peyronie's Disease
Gerald H. Jordan, MD Department of Urology Eastern Virginia Medical School Norfolk, VA Peyronie’s Disease Gerald H. Jordan, MD Department of Urology Eastern Virginia Medical School Norfolk, VA
Slide 110: Peyronie's disease is a scarring phenomenon of the tunica albuginea
Peyronie’s disease is a scarring phenomenon affecting the tunica albuginea of the penis ¹ Scar tissue forms “plaques” that can result in pain with erection, penile curvature/deviation, penile shortening, indentations, and/or erectile dysfunction Histological staining shows fibrin accumulation and ex
Slide 111: Peyronie's Disease in History
FALLOPIUS -- 1561 de la PEYRONIE -- 1743 INDURATIO PLASTICA PENE FALLOPIUS -- 1561 de la PEYRONIE -- 1743 Peyronie’s Disease in History
Slide 112: Peyronie's Disease In History
Peyronie’s Disease In History
Slide 113: Peyronie's Disease
Incurable Reassurance Medical Therapy Surgery Incurable Reassurance Medical Therapy Surgery * Peyronie’s Disease
Slide 114: Peyronie's Disease
Fibrous Lesions - Impede Expansion Curvature And / Or Indentation And / Or Foreshortening Fibrous Lesions - Impede Expansion Curvature And / Or Indentation And / Or Foreshortening Peyronie’s Disease
Slide 115: Peyronie's Disease Update
Peyronie’s Disease Update
Slide 116: Incidence of Peyronie's Disease
Beta Blockers Phenytoin Paget’s Disease Diabetes Mellitus Beta Blockers Phenytoin Paget’s Disease Diabetes Mellitus Incidence of Peyronie’s Disease
Slide 117: Incidence of Peyronie's Disease
Familial Dupuytren’s 15 - 30 % 10 - 40 % Autosomal Dominant Nyberg. JU, 1982; Ralph. JU, 1997 Familial Dupuytren’s 15 - 30 % 10 - 40 % Autosomal Dominant Nyberg. JU, 1982; Ralph. JU, 1997 Incidence of Peyronie’s Disease
Slide 118: Incidence of Peyronie's Disease
1 - 100 Age of Onset - 53yrs (MEAN) Prevalence - 0.4 % Rheu Arth, Hypertension Asymptomatic Prevalence: 22 / 100 Jordan. Cont Urol, 1999, Lindsay. JU, 1991; Smith. Am J Clin Path, 1969 Incidence of Peyronie’s Disease
Slide 119: Incidence of Peyronie's Disease
45 - 65 Years PEAK MID 50’s Loss Of Tissue Elasticity Erectile Dysfunction *** 45 - 65 Years PEAK MID 50’s Loss Of Tissue Elasticity Erectile Dysfunction Incidence of Peyronie’s Disease
Slide 120: Causes of Peyronie's Disease
Trauma - Insertion Septum Localized Aberration Wound Healing Associated With ED Associated Fibrin Deposition Devine. JU, 1997, Jarow. JU, 1997, Somers. JU, 1997 Causes of Peyronie’s Disease Trauma - Insertion Septum Localized Aberration Wound Healing Associated With ED Associated Fibrin Deposition D
Slide 121: Etiology – Trauma
Midline Septal Insertion - Vulnerable with Buckling Devine. JU, 1997, Jarow. JU, 1997, Gelbard, 1993 Etiology - Trauma Midline Septal Insertion - Vulnerable with Buckling Devine. JU, 1997, Jarow. JU, 1997, Gelbard, 1993
Slide 122: Etiology – Genetics
Paget’s Disease Of The Bone Dupuytren's Contracture Certain HLA Subtypes Autoimmune Disease Hyperactive Wound Healing Lyles. J Bone/Mineral Res, 1997, Nyberg. JU, 1982, Nyberg. JU, 1997, Ralph. JU, 1997, Leffell. JU, 1997 Schiavino. Uro, 1997, Stewart. JU, 1994, Devine. Clin Plas Surg, 1988, Diegelm
Slide 123: Pathology
Round Cell Infiltration Obliterated Space of Smith Fibrin Deposits Smith. Am J Clin Path,1969, Devine. JU,1997, Somers. JU,1997 Pathology Round Cell Infiltration Obliterated Space of Smith Fibrin Deposits Smith. Am J Clin Path,1969, Devine. JU,1997, Somers. JU,1997
Slide 124: Pathology – Round Cell Infiltration
Smith. Am J Clin Path,1969, Devine. JU,1997 Pathology – Round Cell Infiltration; Obliterated Space of Smith Smith. Am J Clin Path,1969, Devine. JU,1997
Slide 125: Pathology – Fibrin Deposits
Somers. JU,1997 Pathology – Fibrin Deposits Somers. JU,1997
Slide 126: Pathology
Dense Collagen Decreased Elastin Dystrophic Calcification Cartilaginous Metaplasia Gelbard. JU,1988, Ehrlich. JU,1997 Pathology Dense Collagen Decreased Elastin Dystrophic Calcification Cartilaginous Metaplasia Gelbard. JU,1988, Ehrlich. JU,1997
Slide 127: Anatomy – Tunica Albuginea
Multilayered 1.5 - 3.0 mm thick Incompetent Septum Longitudinal Layer Thinnest 3 - 9 O’clock Hsu et al. Int J Imp,1992, Brock et al. JU,1997 Anatomy - Tunica Albuginea Multilayered 1.5 - 3.0 mm thick Incompetent Septum Longitudinal Layer Thinnest - O’clock Hsu et al. Int J Imp,1992, Brock et al. JU,
Slide 128: Anatomy – Tunica Albuginea
Dorsal Opposite Ventral - Upward Bending Septum Joins Circ Layer - Delamination Ralph. JU,1997, Devine. Clin Plast Surg,1988, Jarow. JU,1997, Devine. JU,1997 Anatomy - Tunica Albuginea
Slide 129: Anatomy – Tunica Albuginea
Plaque Usually Dorsal Devine. JU, 1997, Gelbard. JU, 1993, El-Saka et al. Bju,1997 Anatomy - Tunica Albuginea
Slide 130: Anatomy – Tunica Albuginea
Compliance of the Tunica Collagen is Brittle Elastin Stretches Helical Arrangement Straightens Elastin Stretches Ground Substance Displaces Anatomy - Tunica Albuginea Compliance of the Tunica Collagen is Brittle Elastin Stretches Helical Arrangement Straightens Elastin Stretches Ground Substance Dis
Slide 131: Peyronie's Disease Update
Peyronie’s Disease Update
Slide 132: Molecular Basis of Injury
Repeated Mechanical Stress - Microvascular Trauma Delamination Bleeding Fibrinogen Devine. JU,1997, Jarow. JU,1997, Devine. Clin Plas Surg,1988 Molecular Basis of Injury Molecular Basis of Injury
Slide 133: Molecular Basis of Injury
Pain And Inflammation Vasoactive Factors Is The Inflammatory Response “Trapped?” PDGF-A and PDGF-B, TGF-b1 Diegelman. JU,1997, Van de Water. JU,1997, Somers. JU,1997 Molecular Basis of Injury Molecular Basis of Injury
Slide 134: Molecular Basis of Injury
Causes Increased Connective Tissue Inhibits Collagenases Can Induce It’s Own Production Border. NEJM,1994, Border. J Clin Inves,1992, Moreland. Int J Impot,1998 Implicated in Soft Tissue Fibrosis Implicated in ED Increases Synthesis of Fibroblasts – Fibrosis Wound Healing TGF-b1 Molecular Basis of I
Slide 135: Disease Progression
Active Phase Painful Erections – Sometimes Changing Deformity Secondary Phase Pain Resolves Stable Deformity Gelbard. JU, 1990, Williams. JU, 1970 Active Phase Painful Erections – Sometimes Changing Deformity Secondary Phase Pain Resolves Stable Deformity Gelbard. JU, 1990, Williams. JU, 1970 * Dise
Slide 136: Psychological Aspects
Poorly Defined in the Literature Mentioned Only In Passing Lowsley. JU, 1950, Gelbard. JU,1990, Williams. JU, 1970, Devine. JU, 1974, Mellman, Ju 1978, Pryor. JU, 1979, Ralph. Bju ,1992, Jones. JU, 1984 Poorly Defined in the Literature Mentioned Only In Passing Lowsley. JU, 1950, Gelbard. JU,1990, W
Slide 137: Psychological Aspects
Disturbed Body Image Fearful Of Treatment Many Functional Aspects of ED Like “Death” Denial Ambivalence Anxiety Depression Shame Embarrassment Self Disgust Jones. AUA Update, 1998, Rosen. Data In Process, 2005 Disturbed Body Image Fearful Of Treatment Many Functional Aspects of ED Like “Death” Denia
Slide 138: Psychological Aspects
Youthful Libido Aging Tissues Relate With Intercourse Do Not “ Like ” To Talk About the Problem Jones. AUA Update, 1998, Rosen. Data In Process, 2005 Youthful Libido Aging Tissues Relate With Intercourse Do Not “ Like ” To Talk About the Problem Jones. AUA Update, 1998, Rosen. Data In Process, 2005
Slide 139: Psychological Aspects
Most Patients: Told “End Of Sex Life” Admit … Are Coping Poorly Believe “Sex Is Intercourse” Must Be Told To Keep “Sexual Expression Alive” Jones. AUA Update, 1998 Most Patients: Told “End Of Sex Life” Admit … Are Coping Poorly Believe “Sex Is Intercourse” Must Be Told To Keep “Sexual Expression Ali
Slide 140: Clinical Features
Plaque or Induration: Usually Located Dorsal Septal Insertion Can Be Multiple Can Involve Septal Fibers Patients May Not Be Aware Burford. JU, 1943, Bystrom.Scan J Urol Neph,1976, Williams. BJU, 1980, Furlow. JU, 1975 Plaque or Induration: Usually Located Dorsal Septal Insertion Can Be Multiple Can
Slide 141: Clinical Features
Penile Pain: Usually Only With Erection Usually Not Severe But Can Interfere With Intercourse Spontaneous Improvement The Rule As Inflammation Resolves Burford. JU, 1943, Gelbard. JU, 1990, Williams. BJU, 1980, Furlow. JU, 1975 Clinical Features
Slide 142: Clinical Features
Curvature and/or Deformity: Usually Dorsal Curve Curvature Can Be Complex Lateral or Ventral – Disabling Can Cause Indentation Burford. JU, 1943, Gelbard. JU, 1990, Williams. BJU, 1980, Furlow. JU, 1975 Clinical Features
Slide 143: Clinical Features
Clinical Features
Slide 144: Clinical Features
Erectile Dysfunction: Reported Incidence - Variable Bystrom. Scan J Urol Neph,1976, Levine. JU,1996, Stecker. JU,1984, Jordan. JU,1993, Furlow. JU,1975, Gasior. WJU,1990, Amin. Bj Rad,1993, Montorsi. JU,1994, Pryor. ACTA UROL BELG,1998, Lopez et al. JU,1993, Chilton. BJU,1982, Ralph. BJU,1992, Metz.
Slide 145: Clinical Features
Reduced Elastin - Increased Type III Collagen Associated with Veno-occlusive Problems Cavernosal Fibrosis Can Interfere with Arterial Flow Chisang et al. Euro Urol,1992, Akkus et al. BJU,1997, Ralph. BJU,1992 Clinical Features
Slide 146: Medical Management – Oral
Vitamin E (tocopherol) – antioxidant Potaba (Para Aminobenzoate) Allegra (Seldane) Colchicine Tamoxifen Carnitine (Acetyl-L-Carnitine/Propionyl- L-Carnitine) Trental (Pentoxifylline) Natulan (Procarbazine) Steroids or NSAIDs PDE-5 Inhibitors Vitamin E (tocopherol) – antioxidant Potaba (Para Aminoben
Slide 147: Medical Management – Oral
Rigorous Well Designed / Controlled Studies Are Needed As It Stands Now, The Role Of Oral Therapy To Alter The Progress Of Peyronie's Disease Is Probably Limited To The Acute Phase Of Disease Mynderse And Monga, I J Imp Res, 2002 Medical Management - Oral
Slide 148: Medical Management – Intralesional Injection
Steroids Parathyroid Hormone Orgotein Verapamil Interferon -2b Steroids Parathyroid Hormone Orgotein Verapamil Interferon -2b Medical Management – Intralesional Injection
Slide 149: Medical Management – Topicals
Steroids, Verapamil, Beta – Aminopropionitrile, Orgotein Transcutaneous Absorption of Drug No Blinded / Controlled Studies No Proven Efficacy - Single Reports Only Medical Management - Topicals Steroids, Verapamil, Beta – Aminopropionitrile, Orgotein Transcutaneous Absorption of Drug No Blinded / Co
Slide 150: Medical Management – Iontophoresis / Electromotive Therapy
Steroids, Verapamil, Orgotein, Histamine Enhanced Transcutaneous Absorption Of Drug Using Surface Delivered Heat Or Current No Blinded / Controlled Studies No Proven Efficacy - Single Reports Only Medical Management – Iontophoresis / Electromotive Therapy Steroids, Verapamil, Orgotein, Histamine Enh
Slide 151: Non-Surgical Management
Lithotripsy Questionable Rationale - Ostensibly Mechanical Disruption of the Plaque Enhancing Compliance No Blinded / Controlled Studies No Proven Efficacy To Date, ? Ill Effects on the Erectile Tissue, ? Adjuvant to Intralesional Injection Bellorofonte. Arch Ital Urol Neph Androl,1988 Hauck JU, 200
Slide 152: Medical Management – Combined Therapy
Intralesional Injection And Oral Interferon ~ -2b + Vit E Verapamil + Carnitine Verapamil + Tamoxifen Oral Vit E + Colchicine Lithotripsy + Intralesional Verapamil Birmngham Study Underway Ved + Intralesional Verapamil Study Protocol Under Evaluation Hellstrom, Bju Int 2003, Prieto Castro, Bju Int 2
Slide 153: Medical Management – Future Directions
Investigations Suggest That Part Of The Peyronie’s Process Involves Supression Of “Antifibrotics” Matrixmetalloproteinases 1 Antitrypsin Cyclic GMP Lue . J Sex Med 2005, Hauck. J Sex Med 2005 ~ Medical Management - Future Directions
Slide 154: Surgical Management Indications
When The Deformity Precludes Intercourse Erectile Dysfunction Precludes Intercourse Surgical Management Indications
Slide 155: Surgical Management Pre-operative Assessment
Stable / Quiescent Disease Usually > 1yr from onset of symptoms Stable deformity for 3 – 5 Mos Pain Free Detailed Assessment of Erectile Function CDU DICC True Informed Consent Surgical Management Pre-operative Assessment Stable / Quiescent Disease Usually > 1yr from onset of symptoms Stable deformi
Slide 156: Surgical Management Options
Plication Or Tunical Resection Tunical Resection With Plicating Closure Corporoplasty Nesbitt. Ju 1965, Ebbehoj. Urol 1985, Essed. Urol 1985, Lue. Ju 1998, Geertsen. Bju 1996, Emberger. Bju 1984, Sassine. Urol 1994, Kelami. Bju 1987, Licht. Ju 1997, Yachia. Ju 1990, Rehman. Ju 1997;Pryor And Fitzpat
Slide 157: Surgical Management Options: Plication Or Tunical Resection
Plication Or Tunical Resection Surgical Management Options
Slide 158: Surgical Management Options: Excision / Incision With Grafting
Excision / Incision With Grafting Surgical Management Options Excision / Incision With Grafting
Slide 159: Surgical Management Options
Surgical Management Options
Slide 160: Surgical Management Options: Prosthetic Implantation
Prosthetic Implantation With Straightening Pryor. Churchill-Livingston, 1987, Wilson. JU, 1994, Montague. JU, 1006, Knoll. Urol, 1990, Eigner. JU, 1991, Carson. Ijir, 1998, Carwson. Ijir, 2002 Surgical Management Options
Slide 161: Medical Management – XIAFLEX
Clostridial Collagenase (XIAFLEX) Creation of “Chemical Incisions” with Initiation of Remodeling Blinded / Controlled Studies Underway Available Only on Protocol Gelbard. Urol Res, 1982, Gelbard. JU,1985, Gelbard. JU,1993, National Collagenase Study Group, Jordan. J Sexual Medicine, 2007 Medical Man
Slide 162: Safety and Efficacy of XIAFLEX in Peyronie's Disease
Safety and Efficacy of Injectable Mixed Collagenase Subtypes (XIAFLEX) in the Treatment of Peyronie’s Disease Safety and Efficacy of Injectable Mixed Collagenase Subtypes (XIAFLEX) in the Treatment of Peyronie’s Disease
Slide 163: Objectives
To assess the impact of injectable mixed collagenase subtypes (XIAFLEX, Auxilium) on the angle of penile deviation and plaque size To assess the tolerability and safety of XAIFLEX for the treatment of Peyronie’s disease Objectives
Slide 164: Methods: Study Design
Baseline Week 12 Month 6 Follow-up Month 9 Follow-up 3 injections (7 10 d) 3 injections (7 10 d) X X X X X X Baseline Week 12 Month 6 Follow-up Month 9 Follow-up 3 injections (5 10 d) 3 injections (5 10 d) Week 6 3 injections (5 10 d) X X X X X X X X X Methods: Study Design Study A (N=25) Study B (N
Slide 165: Methods: Patients
Key inclusion criteria: Men aged 18 75 years Diagnosis of Peyronie’s disease Key exclusion criteria: Prior surgery for Peyronie’s disease Extensively calcified plaque Substantial erectile deficits due to Peyronie’s disease Penile bend <20 degrees Sexual dysfunction due to other causes Methods: Patie
Slide 166: Assessment of Efficacy and Tolerability
Study A: Primary: changes from baseline in the angle of deviation and plaque size Secondary: patient responses on VAS for pain and sexual function Secondary: investigators’ global evaluation of change Study B: Primary: patients’ responses on the Peyronie’s Patient Questionnaire at month 9 Secondary:
Slide 167: Results: Demographics and Disposition
Study A: 25 men enrolled and 18 completed the study Mean age was 55 years; 92% were white Mean duration of illness was 39 months Study B: 10 men enrolled; 9 completed the study Mean age was 58 years; 90% were white Mean duration of illness was 32 months Results: Demographics and Disposition Study A:
Slide 168: Results: Clinical Success, Deviation Angle
58 53 35 0 20 40 60 80 100 M3 M6 M9 50 100 100 89 0 20 40 60 80 100 W6 M3 M6 M9 *Clinical success: 25% reduction in the angle of deviation. Results: Clinical Success,* Deviation Angle Study A Study B
Slide 169: Results: Clinical Success, Plaque Size
95 65 67 0 20 40 60 80 100 M3 M6 M9 *Clinical success: 25% reduction in plaque size. Results: Clinical Success,* Plaque Size Study A
Slide 170: Results: Mean Change From Baseline in Deviation Angle and Plaque Size
Deviation Angle ( ) Plaque Length (cm) Plaque Width (cm) Study A Study B Study A Study B Study A Study B Baseline 52.8 50.2 5.8 7.85 0.80 0.48 W6 NA 15.2* NA 0.05 NA 0.16 M3 12.7* 20.6 † 0.94 † 1.59 0.13* 0.11 M6 11.1 † 28.4 † 0.48 ‡ 0.11 0.15 ‡ 0.21 ‡ M9 6.6 26.2 † 0.68 0.00 0.12 ‡ 0.18 * P 0.007 v
Slide 171: Results: Peyronie's Patient Questionnaire (Study B)
Patient-reported improvements in sexual function were observed for: Enjoyment of intercourse ( P =0.023) Satisfaction with sexual relationships ( P =0.043) Freedom from pain during erection ( P =0.009) At baseline, 4 patients reported no sexual activity, and at month 9, 100% (9/9) were sexually acti
Slide 172: Results: Physical Symptoms (Study B)
Pain with erection: resolved in 6 patients Plaque palpability: disappeared in 4 patients with moderate-to-severe palpation Penile indentation: disappeared in 3 patients and improved from severe to moderate in 1 patient Penile shortening: improved from severe to moderate in 1 patient Penile numbness:
Slide 173: Results: Investigators' Global Assessment of Patients
59 53 56 0 20 40 60 80 100 M3 M6 M9 50 67 67 67 0 20 40 60 80 100 W6 M3 M6 M9 Results: Investigators’ Global Assessment of Patients Much Improved/Very Much Improved Study A Study B
Slide 174: Adverse Events: Study A
Relationship to Study Drug, n (%) Adverse Event Possibly Probably Definitely Reproductive system 1 (4) 1 (4) 14 (56) Erectile disturbance 0 (0) 1 (4) 0 (0) Penile disorder NOS 0 (0) 0 (0) 5 (20) Penile pain 1 (4) 0 (0) 12 (48) Penile swelling 0 (0) 0 (0) 6 (24) Skin and subcutaneous tissue disorders
Slide 175: Adverse Events: Study B
Treatment-Related Adverse Event, n (%) Total (N=10) General disorders and administration site conditions 5 (50) Local swelling 2 (20) Suprapubic pain 4 (40) Injury, poisoning, and procedural pain 10 (100) Contusion 10 (100) Reproductive system and breast disorders 9 (90) Erectile dysfunction 1 (10)
Slide 176: Adverse Events
The most common treatment-related adverse events were localized administration site reactions of mild intensity and of limited duration (typically within 3 weeks) The most common adverse events were contusion, penile pain, and ecchymosis All adverse events resolved without medical intervention Adver
Slide 177: Conclusions
XIAFLEX, administered in up to 3 series of multiple injections, appears to be effective for the treatment of Peyronie’s disease Treatment with XIAFLEX was generally well tolerated Larger controlled clinical trials are needed to confirm these promising results and are in the process of development Co
Slide 178: Peyronie's Disease
Gerald H. Jordan, MD Department of Urology Eastern Virginia Medical School Norfolk, VA Peyronie’s Disease Gerald H. Jordan, MD Department of Urology Eastern Virginia Medical School Norfolk, VA
Slide 179: Development Plans for Peyronie's Disease
Development Plans for Peyronie ’ s Disease Jyrki Mattila Executive Vice President R&D
Slide 180: Preclinical local tolerability study
Preclinical local tolerability study • Four anatomic structures exposed to Xiaflex ™ ~ Tunica albuginea, Corpus cavernosum, NAV-complex and Urethra • Single dose and repeated dose groups • Dosing mimics expected clinical use • Histopathology, toxicokinetics and immunogenecity to be recorded • Study
Slide 181: Phase 2b study
Phase 2 b study • Injections of 0.58 mg in 0.25 mL volume given into Peyronie’s plaque ~ Two regimens of either six or nine total doses to be compared Patient Reported Outcome Survey likely to be used as a primary endpoint ~ AUXL developed its own proprietary questionnaire for Peyronie’s disease ~ F
Slide 182: Market Overview for XIAFLEX: Peyronie's Disease
Market Overview for XIAFLEX: Peyronie ’ s Disease Roger D. Graham, Jr. Executive Vice President Sales & Marketing
Slide 183: Market Research Methodology
Market Research Methodology • Approximately 600 Urologists/Surgeons ~ 415 U.S. Physicians ~ 193 E.U. Physicians Qualitative and Quantitative Research ~ on in depth interviews with KOLs (High Treaters) ~ Web based Surveys ~ Second quantitative study designed to provide 95% confidence level and 7.5% m
Slide 184: Surgeon Motivation to Use Xiaflex
Surgeon Motivation to Use Xiaflex • Seeking effective treatment options ~ No effective medical therapy ~ Surgery is last resort; many patients choose not to have it ~ Penile shortening ~ Erectile dysfunction/impotence ~ Many surgical patients dissatisfied with outcomes High Interest In XIAFLEX ~ Hig
Slide 185: Reimbursement and Surgical Costs
Reimbursement and Surgical Costs • All payers (US & EU) anticipate coverage for XIAFLEX • New CPT codes may be needed • Ambulatory (70%) & In-Patient (30%) Surgery ~ Approximate Cost (Blended) $ 13,000* • In-patient Surgery ~ $ 23,000** * Pharmetrics ** Verispan Approximate Cost
Slide 186: XIAFLEX Potential: Peyronie's Disease
XIAFLEX Potential: Peyronie’s Disease Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates ~210,000 ~ 135,000 in U.S. ~ 75,000 in Europe Source: Auxilium rese
Slide 187: Xiaflex Commercial Opportunity
Xiaflex Commercial Opportunity We believe: • High need opportunity (MD and Patient) • Surgeons and patients prefer non-invasive treatment • Early indication that each patient will require 6 to 9 vials of Xiaflex • Reimbursement environment is positive • Peyronie’s represents a second significant com
Slide 188: XIAFLEX (clostridial collagenase for injection)
AIAFLEX lostridal colagenase for injection
Auxilium Pharmaceuticals — Investor Day (October 2007) on 6ix